Medigene acquires Trianta for $5M up front, $8M milestones
By Cormac Sheridan
Monday, January 27, 2014
Medigene AG is paying €4 million (US$5.5 million) in stock and could pay up to €5.875 million more in milestones to acquire newly formed start-up cancer immunotherapy firm Trianta Immunotherapies GmbH, which already has two clinical trials under way.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.